This invention generally relates to devices and methods for treating tissue surrounding a body cavity, such as a site from which cancerous, pre-cancerous, or other tissue has been removed.
In diagnosing and treating certain medical conditions, it is often desirable to perform a biopsy, in which a specimen or sample of tissue is removed for pathological examination, tests and analysis. A biopsy typically results in a biopsy cavity occupying the space formerly occupied by the tissue that was removed. As is known, obtaining a tissue sample by biopsy and the subsequent examination are typically employed in the diagnosis of cancers and other malignant tumors, or to confirm that a suspected lesion or tumor is not malignant. Treatment of cancers identified by biopsy may include subsequent removal of tissue surrounding the biopsy site, leaving an enlarged cavity in the patient's body. Cancerous tissue is often treated by application of radiation, by chemotherapy, or by thermal treatment (e.g., local heating, cryogenic therapy, and other treatments to heat, cool, or freeze tissue).
Cancer treatment may be directed to a natural cavity, or to a cavity in a patient's body from which tissue has been removed, typically following removal of cancerous tissue during a biopsy or surgical procedure. For example, U.S. Pat. No. 6,923,754 to Lubock and U.S. patent application Ser. No. 10/849,410 to Lubock, the disclosures of which are all hereby incorporated by reference in their entireties, describe devices for implantation into a cavity resulting from the removal of cancerous tissue which can be used to deliver cancer treatments to surrounding tissue. One form of radiation treatment used to treat cancer near a body cavity remaining following removal of tissue is “brachytherapy” in which a source of radiation is placed near to the site to be treated.
Lubock above describes implantable devices for treating tissue surrounding a cavity left by surgical removal of cancerous or other tissue that includes an inflatable balloon constructed for placement in the cavity. Such devices may be used to apply one or more of radiation therapy, chemotherapy, and thermal therapy to the tissue surrounding the cavity from which the tissue was removed. The device may be configured to receive a solid or a liquid radiation source or both. Radiation treatment is applied to tissue adjacent the balloon of the device by placing radioactive material such as radioactive “seeds” in a delivery lumen within a distal treatment location. Such treatments may be repeated if desired. While the radiation source is typically a solid radiation source, a radiation source such as a miniature or micro-miniature x-ray tube may also be used (e.g. U.S. Pat. No. 6,319,188). The x-ray tubes are small, flexible and are believed to be maneuverable enough to reach the desired treatment location within a patient's body. The radiation source is to be removed following each treatment session, or remains in place as long as the balloon remains within the body cavity. These inflatable treatment delivery devices and systems are useful to treat cancer in tissue adjacent a body cavity.
However, radiation, chemotherapy, thermal treatment, and other cancer treatments often have deleterious effects on healthy tissue in addition to the desired effects on cancerous tissue. In such treatments, care must be taken to direct the maximum treatment effects to diseased tissue while minimizing its delivery or effects on healthy tissue. For example, radiation treatment may be most effective when only the portion of tissue requiring treatment receives the radiation and where surrounding healthy tissue is unaffected. Tissue cavities typically are not uniform or regular in their sizes and shapes, so that differences in dosages applied to different regions of surrounding tissue, including “hot spots” and regions of relatively low dosage, often result from radiation treatment.
Features of a treatment delivery device for treating tissue adjacent a body cavity, included in the Contura™ multilumen balloon catheter, have been disclosed in U.S. Pat. No. 6,923,754. This patent describes applying a partial-vacuum or suction to bring tissue towards an inflated balloon around a radiation source and allows for uniform application of radiation to tissue surrounding a body cavity. Additional features are described in copending application Ser. No. 11/593,784 and Ser. No. 11/593,789 relating to multilumen catheters which allow a greater degree of flexibility in asymmetric radiation source placement within the body cavity. However, some of these catheter constructions are complex and difficult to manufacture.
This invention is generally directed to a balloon catheter for treating a patient's body cavity or other intracorporeal site (hereinafter collectively referred to as a body cavity) and methods for such treatments. The invention is particularly suitable for treating tissue adjacent to a body cavity formed by the removal of tissue such as from a patient's breast in a lumpectomy.
More specifically, a device embodying features of the invention has an elongated shaft, a distal end, a distal shaft portion which has a treatment location and an inner lumen extending to the distal shaft portion. The elongated shaft has a shaft wall which at least in part defines an inner lumen and which has a plurality of lumens within the wall. The shaft wall in the distal shaft portion has a plurality of separated longitudinal wall segments having at least one lumen extending therein. A support member preferably extends within the distal shaft portion to support the separated longitudinal wall segments and preferably has a plurality of recesses configured to receive and support the separated longitudinal wall segments. The recesses of the support member preferably place the wall segments into a convex arcuate configuration away from a central longitudinal axis. The support member preferably has an inner lumen in fluid communication with the inner lumen defined by the shaft wall and preferably continues and is in fluid communication with the inner lumen of a tubular member within the inner lumen of the elongated shaft. The distal ends of the separated longitudinal wall segments are secured to the distal end of the support member or a distal tip of the elongated shaft with the separated wall segments in convex arcuate configurations away from the longitudinal axis. A distal tip at the distal end of the shaft preferably closes off the inner lumen of the support member and one or more of the lumens which extend within the wall segments.
The inner lumen of the elongated shaft within the treatment location and at least one of the lumens extending within the separated longitudinal wall segments are configured to receive a radiation source so as to treat tissue adjacent to the distal shaft portion. The lumens may be coated with a lubricous material or lined with a tubular member with an inner lumen having suitable lubricous properties (or a lubricous material thereon) to allow radiation sources to be readily advanced therein.
Preferably, the catheter has an enlarged or enlargeable cavity filling member at the treatment location, such as an inflatable which at least in part fills the body cavity. The cavity filling member is mounted onto the distal shaft portion surrounding the separated longitudinal wall segments so that when expanded will hold tissue lining the body cavity in a desired configuration. The proximal end of the balloon is secured proximal to the arcuate separated longitudinal segments and the distal end is secured to the distal ends of the separated longitudinal wall segments, the distal tip or both.
The distal tip of the catheter preferably has proximally extending plugs members to close off the lumens within the wall segments and preferably, the inner lumen of the support member.
One or more of the lumens in the shaft wall may be used to deliver inflation fluid to the interior of a balloon surrounding the distal shaft portion. One or more of the lumens in the shaft wall may be connected to a vacuum source to provide a vacuum to regions surrounding the distal shaft portion proximal and/or distal to the balloon through one or more vacuum ports therein, such as described in U.S. Pat. No. 6,923,754 and co-pending application Ser. No. 10/849,410 filed on May 19, 2004, both of which are assigned to the SenoRx, Inc., present assignee. Application of a vacuum within the inner lumen aspirates fluid in the cavity through one or more vacuum ports and the vacuum within the body cavity pulls tissue defining the cavity onto the exterior of the cavity filling member deployed within the cavity.
The arcuate configuration of the longitudinal wall segments allows for asymmetric deployment of radiation sources within the body cavity as described in co-pending application Ser. No. 11/593,784, and Ser. No. 11/593,789, both filed on Nov. 6, 2006, so as to be closer to a first portion of tissue surrounding the cavity than a second portion of tissue surrounding the cavity opposite the first tissue portion. This facilitates the radiation source to be offset or capable of being offset within the body cavity so that tissue of one portion of the cavity closer to the source receives more intense radiation treatment and tissue of the second portion further from the source receives less radiation.
The elongated shaft may also have one or more radiation shielding components designed to reduce or minimize damaging irradiation of healthy tissue surrounding the body cavity while treating nearby areas having diseased tissue with radiation emitted from the radiation source. The radiation shielding components include one or more radiation shields disposed about a delivery shaft containing the radiation source. Suitable radiation shielding components are describe in co-pending application Ser. No. 11/593,678 and 11/593,952, both filed on Nov. 6, 2006, both assigned to SenoRx, Inc. the present assignee.
A method for treating a body cavity or other intracorporeal site of a patient includes delivering a treatment agent such as a radiation source to a body cavity to treat the desired tissue while minimizing damaging irradiation of healthy tissues. More specifically, a method for treating a body cavity or intracorporeal site includes providing a device having an elongate shaft with a proximal end, a distal end, and a treatment location in a distal portion of the shaft. The method further includes providing a radiation source configured to be deposited in the treatment location and a radiation shielding component partially encircling the treatment location which is configured to control at least in part the emission of radiation emitted from the treatment location. The device is advanced within the patient until the treatment location of the device is deployed within the body cavity or site and the radiation source is positioned within the treatment location. The radiation shielding component is positioned to shield portions of the body cavity from radiation emitted from the radiation source.
A patient's skin is susceptible to damage from radiation delivered by isotopes (e.g. seeds) or x-ray catheters in a lumen of a radiation balloon catheter if the radiation source is too close to the skin. Generally, radiation treatments using a radiation balloon catheter is usually not performed on patients where the body cavity (e.g. from a lumpectomy) is less than 5 mm, sometimes less than 7 mm from the patient's skin. Additionally, over inflation of the balloon can thin and stretch the skin. The application of a vacuum to the body cavity can help by pulling the tissue to the balloon and increased cavity to skin surface distances would result. However, in some instances it would still be too thin to treat. The number of potential patient's which are suitable candidates for treatments with the present device is significantly increased due to reducing the potential for skin tissue damage.
The surface (inside or outside) of the balloon or within the balloon wall may be provided with indicator marks for location or orientation detection during the procedures. For example, dots or lines to help place balloon in appropriate position under CT, x-ray or fluoroscopy. The indicator marks may be radiopaque. Alternatively, or additionally, ultrasound indicators or MRI and direct visual indicators could be incorporated. The indicator marks may extend along the catheter shaft to help with placement of the catheter device during the treatment procedure and the orientation of the off-set lumen and shield.
One attractive additional feature for brachytherapy for breast lumpectomy sites is to provide heat to the tissue lining of the cavity either simultaneously with or sequentially to (before or after) irradiation. Suitable means to do this are described in U.S. Pat. No. 5,106,360 (Ishiwara et al.) wherein brachytherapy catheter is provided with heating electrical coils in the treatment region of the catheter. Other means such as inflation fluid at elevated temperatures may be employed. Generally, tissue temperature must be less than 100°, preferably less than 60° C. to avoid excess damage to surrounding health tissue.
The present invention provides a brachytherapy catheter device which is effective, easy to use and which is easy to manufacture. These and other advantages of the present invention are described in more detail in the following written description and the accompanying exemplary drawings.
The present invention is directed to devices and methods for treatment of a patient's body cavity, particularly to deliver asymmetrical radiation into a body cavity such as a cavity left after removal of tissue from the site. While the detailed description is directed to a device configured for treating a patient' breast after tissue removal such as in a lumpectomy, other body sites may also be treated with the device.
The hub 16 has a ridge 34 which is aligned with marker line 35 to provide the physician or other professional the orientation of the treatment location 13. The elongated shaft 11 may also be provided with depth markings to help in the placement of the balloon 15 within the cavity.
As shown best in
As shown in
As best shown in
The brachytherapy catheter device 10 is readily manufactured. The elongated shaft 11 is extruded, preferably with the lumens 36-43 within the wall and the central lumen 46. The distal shaft portion 14 is cut by a suitable cutting member such as a razor or knife like member to form the plurality of separated longitudinal wall segments 49-52. The support member 48 is preferably machined from an extruded tubular polymeric product to form the recesses 53-56 and overall shape and centrally placed within the separated longitudinal wall segments. A tubular member 32 is positioned within the inner lumen of the elongated shaft 11 and may continue to the distal end of the shaft through the inner lumen of the support member 48. The distal tip 12 is secured to the distal end of the shaft 11 and support member 48 with plug members 60-63 inserted into the lumens within the wall segments 49-52 and central plug member 64 within the lumen of the centrally disposed tubular member 32. The distal tip 12 is preferably preformed with the vacuum ports 45. The distal ends of the separated longitudinal wall segments are secured to the distal end of the device, preferably to the distal end of the support member. The balloon 15 is mounted about the wall segments 49-52 and support member 48 with the distal end of the balloon secured to the distal end of the wall segments and support member and the proximal end of the balloon is secured to the elongated shaft proximal to the separated longitudinal wall segments. Preferably, strands or sutures are wrapped around each of the mounted ends of the balloon 15 to provide further support to the ends. The proximal end of the device 10 is similar to the brachytherapy devices previously described in copending application Ser. Nos. 11/593,784 and 11/593,789 previously referred to herein.
A body cavity within a patient may be treated with the device 10 by inserting the distal shaft portion 13 into the desired body cavity, inflating the balloon 15 with inflation fluid to secure the device within the patient and applying a vacuum to either the distal or proximal vacuum ports or both to conform the tissue lining the cavity to the exterior of balloon 15. A radiation source is advanced through one or more of the source delivery lumens until the radiation source is properly positioned within the treatment location 13 (or prepositioned therein). The radiation source (not shown) is maintained at the treatment location 13 for a prescribe period of time, usually less than 30 minutes and typically a few (5-10) minutes. The radiation source may be placed at several places within the treatment location with in one or multiple source lumens. At the end of the treatment time, the radiation source may be removed from device 10 or the entire device may be withdrawn from the patient. Preferably, the device is left in place so that further radiation treatments may be performed.
The radiation source for the brachytherapy device 10 can include a solid, liquid or slurried radiation source. Suitable liquid radiation sources include, for example, a liquid containing a radioactive iodine isotope (e.g., I125 or I131), a slurry of a solid isotope, for example, 198Au or 169Yb, or a gel containing a radioactive isotope. Liquid radiation sources are also commercially available (e.g., Iotrex®, Proxima Therapeutics, Inc., Alpharetta, Ga.). The solid radiation source may be a radioactive microsphere available from 3M Company of St. Paul, Minn. A micro miniature x-ray source may also be utilized. The radiation source may be either preloaded into the device 10 at the time of manufacture or may be loaded into the device 10 before or after placement into a body cavity or other site of a patient. Solid radionuclides suitable for use with a device 10 embodying features of the present invention are currently generally available as brachytherapy radiation sources (e.g., I-Plant™ Med-Tec, Orange City, Iowa.). Radiation may also be delivered by a device such as the x-ray tube of U.S. Pat. No. 6,319,188. The x-ray tubes are small, flexible and are believed to be capable of being maneuverable enough to reach the desired location within a patient's body.
The source delivery lumens of brachytherapy device 10 having features of the invention can be provided with a lubricious coating, such as a hydrophilic material. The lubricious coating preferably is applied to the elongate shaft 12 or to the cavity filling member, if one is present or both to reduce sticking and friction during insertion of a device 10. Hydrophilic coatings such as those provided by AST, Surmodics, TUA Systems, Hydromer, or STS Biopolymers are suitable.
A device 10 having features of the invention may also include an antimicrobial coating that covers all or a portion of the device 10 to minimize the risk of introducing of an infection during extended treatments. The antimicrobial coating preferably is comprised of silver ions impregnated into a hydrophilic carrier. Alternatively the silver ions are implanted onto the surface of the device 10 by ion beam deposition. The antimicrobial coating preferably is comprised of an antiseptic or disinfectant such as chlorhexadiene, benzyl chloride or other suitable biocompatible antimicrobial materials impregnated into hydrophilic coatings. Antimicrobial coatings such as those provided by Spire, AST, Algon, Surfacine, Ion Fusion, or Bacterin International would be suitable. Alternatively a cuff member covered with the antimicrobial coating is provided on the elongated shaft of the delivery device 10 at the point where the device 10 enters the skin.
While particular forms of the invention have been illustrated and described herein, it will be apparent that various modifications and improvements can be made to the invention. Additional details of the brachytherapy catheter devices may be found in the patents and applications incorporated herein. To the extent not otherwise disclosed herein, materials and structure may be of conventional design.
Moreover, individual features of embodiments of the invention may be shown in some drawings and not in others, but those skilled in the art will recognize that individual features of one embodiment of the invention can be combined with any or all the features of another embodiment. Accordingly, it is not intended that the invention be limited to the specific embodiments illustrated. It is therefore intended that this invention be defined by the scope of the appended claims as broadly as the prior art will permit.
Terms such as “element”, “member”, “component”, “device”, “means”, “portion”, “section”, “steps” and words of similar import when used herein shall not be construed as invoking the provisions of 35 U.S.C §112(6) unless the following claims expressly use the terms “means for” or “step for” followed by a particular function without reference to a specific structure or a specific action. All patents and all patent applications referred to above are hereby incorporated by reference in their entirety.
This application is related to provisional application Ser. No. 61/062,179, filed on Jan. 24, 2008, which is incorporated herein in its entirety and which is relied upon for priority.
Number | Name | Date | Kind |
---|---|---|---|
3324847 | Zoumboulis | Jun 1967 | A |
3872856 | Clayton | Mar 1975 | A |
3975350 | Hudgin et al. | Aug 1976 | A |
4119094 | Micklus et al. | Oct 1978 | A |
4454106 | Gansow et al. | Jun 1984 | A |
4690677 | Erb | Sep 1987 | A |
4763642 | Horowitz | Aug 1988 | A |
4929470 | Rittenhouse et al. | May 1990 | A |
4998930 | Lundahl | Mar 1991 | A |
5059166 | Fischell et al. | Oct 1991 | A |
5106360 | Ishiwara et al. | Apr 1992 | A |
5167622 | Muto | Dec 1992 | A |
5199939 | Dake et al. | Apr 1993 | A |
5227969 | Waggener et al. | Jul 1993 | A |
5259847 | Trambert | Nov 1993 | A |
5302168 | Hess | Apr 1994 | A |
5312356 | Engelson et al. | May 1994 | A |
5314518 | Ito et al. | May 1994 | A |
5342305 | Shonk | Aug 1994 | A |
5381504 | Novack et al. | Jan 1995 | A |
5411466 | Hess | May 1995 | A |
5417687 | Nardella et al. | May 1995 | A |
5428658 | Oettinger et al. | Jun 1995 | A |
5429582 | Williams | Jul 1995 | A |
5503613 | Weinberger | Apr 1996 | A |
5535817 | Dunne | Jul 1996 | A |
5566221 | Smith et al. | Oct 1996 | A |
5603991 | Kupiecki et al. | Feb 1997 | A |
5611767 | Williams | Mar 1997 | A |
5616114 | Thorton et al. | Apr 1997 | A |
5621780 | Smith et al. | Apr 1997 | A |
5653683 | D'Andrea | Aug 1997 | A |
5662580 | Bradshaw et al. | Sep 1997 | A |
5704926 | Sutton | Jan 1998 | A |
5720717 | D'Andrea | Feb 1998 | A |
5759173 | Preissman et al. | Jun 1998 | A |
5782742 | Crocker et al. | Jul 1998 | A |
5820594 | Fontirroche et al. | Oct 1998 | A |
5820717 | Siegenthaler | Oct 1998 | A |
5863285 | Coletti | Jan 1999 | A |
5908406 | Ostapchenko et al. | Jun 1999 | A |
5913813 | Williams et al. | Jun 1999 | A |
5916143 | Apple et al. | Jun 1999 | A |
5919473 | Elkhoury | Jul 1999 | A |
5924973 | Weinberger | Jul 1999 | A |
5931774 | Williams et al. | Aug 1999 | A |
5935098 | Blaisdell et al. | Aug 1999 | A |
5993972 | Reich et al. | Nov 1999 | A |
6022308 | Williams | Feb 2000 | A |
6033357 | Ciezki et al. | Mar 2000 | A |
6036631 | McGrath et al. | Mar 2000 | A |
6083148 | Williams | Jul 2000 | A |
6086970 | Ren | Jul 2000 | A |
6093142 | Ciamacco, Jr. | Jul 2000 | A |
6095966 | Chornenky et al. | Aug 2000 | A |
6143013 | Samson et al. | Nov 2000 | A |
6200257 | Winkler | Mar 2001 | B1 |
6217565 | Cohen | Apr 2001 | B1 |
6251059 | Apple et al. | Jun 2001 | B1 |
6256529 | Holupka et al. | Jul 2001 | B1 |
6282142 | Miyawaki | Aug 2001 | B1 |
6378137 | Hassan et al. | Apr 2002 | B1 |
6390967 | Forman et al. | May 2002 | B1 |
6390968 | Harmon | May 2002 | B1 |
6390992 | Morris et al. | May 2002 | B1 |
6398708 | Hastings et al. | Jun 2002 | B1 |
6413203 | Sahatjian | Jul 2002 | B1 |
6413204 | Winkler et al. | Jul 2002 | B1 |
6416492 | Nielson | Jul 2002 | B1 |
6458069 | Tam et al. | Oct 2002 | B1 |
6482142 | Winkler et al. | Nov 2002 | B1 |
6512942 | Burdette et al. | Jan 2003 | B1 |
6527693 | Munro, III et al. | Mar 2003 | B2 |
6540655 | Chin et al. | Apr 2003 | B1 |
6605030 | Weinberger | Aug 2003 | B2 |
6610013 | Fenster et al. | Aug 2003 | B1 |
6615070 | Lee | Sep 2003 | B2 |
6673006 | Winkler | Jan 2004 | B2 |
6706014 | Banik et al. | Mar 2004 | B2 |
6723052 | Mills | Apr 2004 | B2 |
6746392 | Stiger et al. | Jun 2004 | B2 |
6752752 | Geitz | Jun 2004 | B2 |
6770058 | Liprie | Aug 2004 | B1 |
6913600 | Valley et al. | Jul 2005 | B2 |
6923754 | Lubock | Aug 2005 | B2 |
6955641 | Lubock | Oct 2005 | B2 |
6983754 | Anderson et al. | Jan 2006 | B1 |
7098463 | Adamovics | Aug 2006 | B2 |
7107089 | Lee | Sep 2006 | B2 |
7171255 | Holupka et al. | Jan 2007 | B2 |
7201715 | Burdette et al. | Apr 2007 | B2 |
7214178 | Lubock | May 2007 | B2 |
7322929 | Lovoi | Jan 2008 | B2 |
7404791 | Lunares et al. | Jul 2008 | B2 |
7407476 | Lubock et al. | Aug 2008 | B2 |
7413539 | Lubock et al. | Aug 2008 | B2 |
7465268 | Lubock et al. | Dec 2008 | B2 |
7476235 | Diederich et al. | Jan 2009 | B2 |
7497819 | White et al. | Mar 2009 | B2 |
7497820 | White et al. | Mar 2009 | B2 |
7513861 | Klein et al. | Apr 2009 | B2 |
7783006 | Stewart et al. | Aug 2010 | B2 |
7885382 | Stewart et al. | Feb 2011 | B2 |
7887476 | Hermann et al. | Feb 2011 | B2 |
20010016725 | Valley et al. | Aug 2001 | A1 |
20010049464 | Ganz | Dec 2001 | A1 |
20010051669 | Mcghee | Dec 2001 | A1 |
20020045893 | Lane et al. | Apr 2002 | A1 |
20020055666 | Hunter et al. | May 2002 | A1 |
20020095114 | Palasis | Jul 2002 | A1 |
20020177804 | Saab | Nov 2002 | A1 |
20030144570 | Hunter et al. | Jul 2003 | A1 |
20040039437 | Sparer et al. | Feb 2004 | A1 |
20040054366 | Davison et al. | Mar 2004 | A1 |
20040087827 | Lubock | May 2004 | A1 |
20040116767 | Lebovic et al. | Jun 2004 | A1 |
20040215048 | Lubock | Oct 2004 | A1 |
20040260142 | Lovoi | Dec 2004 | A1 |
20050061771 | Murphy | Mar 2005 | A1 |
20050080313 | Stewart et al. | Apr 2005 | A1 |
20050124843 | Singh | Jun 2005 | A1 |
20050182286 | Lubock | Aug 2005 | A1 |
20050240073 | Apffelstaedt et al. | Oct 2005 | A1 |
20050240074 | Lubock | Oct 2005 | A1 |
20050277577 | Hunter et al. | Dec 2005 | A1 |
20060020156 | Shukla | Jan 2006 | A1 |
20060020256 | Bell et al. | Jan 2006 | A1 |
20060100475 | White et al. | May 2006 | A1 |
20060116546 | Eng | Jun 2006 | A1 |
20060136051 | Furst et al. | Jun 2006 | A1 |
20060167416 | Mathis et al. | Jul 2006 | A1 |
20060173233 | Lovoi | Aug 2006 | A1 |
20060173235 | Lim et al. | Aug 2006 | A1 |
20060205992 | Lubock et al. | Sep 2006 | A1 |
20070005003 | Patterson et al. | Jan 2007 | A1 |
20070055144 | Neustadter et al. | Mar 2007 | A1 |
20070106108 | Hermann et al. | May 2007 | A1 |
20070167666 | Lubock et al. | Jul 2007 | A1 |
20070167668 | White et al. | Jul 2007 | A1 |
20070191667 | Lubock et al. | Aug 2007 | A1 |
20070270627 | Cutrer et al. | Nov 2007 | A1 |
20080057298 | Finley | Mar 2008 | A1 |
20080064915 | Lubock | Mar 2008 | A1 |
20080091055 | Nguyen et al. | Apr 2008 | A1 |
20080188705 | Lubock et al. | Aug 2008 | A1 |
20080221444 | Ritchie et al. | Sep 2008 | A1 |
20080228025 | Quick | Sep 2008 | A1 |
20080228150 | Jones et al. | Sep 2008 | A1 |
20080281142 | Lubock et al. | Nov 2008 | A1 |
20080281143 | Lubock et al. | Nov 2008 | A1 |
20080287801 | Magnin et al. | Nov 2008 | A1 |
20090030259 | Quick | Jan 2009 | A1 |
20090124845 | Lubock et al. | May 2009 | A1 |
20090171157 | Diederich et al. | Jul 2009 | A1 |
20100010287 | Lubock | Jan 2010 | A1 |
20100048979 | Jones et al. | Feb 2010 | A1 |
Number | Date | Country |
---|---|---|
0 536 440 | Oct 1991 | EP |
0 642 766 | Mar 1995 | EP |
0 693 293 | Jan 1996 | EP |
0 719 571 | Jul 1996 | EP |
0 853 957 | Jul 1998 | EP |
0 867 200 | Sep 1998 | EP |
1 051 990 | Nov 2000 | EP |
1070514 | Jan 2001 | EP |
1 402 922 | Mar 2004 | EP |
1541188 | Jun 2005 | EP |
1 618 924 | Jan 2006 | EP |
10137250 | May 1998 | JP |
2001 120561 | May 2001 | JP |
2177350 | Dec 2001 | RU |
WO 9520241 | Jul 1995 | WO |
9712540 | Apr 1997 | WO |
WO 9745053 | Dec 1997 | WO |
9815315 | Apr 1998 | WO |
9934869 | Jul 1999 | WO |
WO 0114011 | Mar 2001 | WO |
WO 0143826 | Jun 2001 | WO |
WO 0158346 | Aug 2001 | WO |
WO 0209599 | Feb 2002 | WO |
WO 02069862 | Sep 2002 | WO |
WO 2004043531 | May 2004 | WO |
WO 2005037363 | Apr 2005 | WO |
2005039655 | May 2005 | WO |
WO 2005039665 | May 2005 | WO |
WO 2005067442 | Jul 2005 | WO |
WO 2007027831 | Mar 2007 | WO |
WO 2007143560 | Dec 2007 | WO |
Entry |
---|
Abstracts of the 11th International Conference on Brain tumor Research and Therapy Oct. 31-Nov. 3, 1995, Silverado Country Club and Resort, Napa, California, Journal of Neuro-Oncology 28:72, 1996. |
Johannesen, T.B. et al, “Intracavity Fractioned Balloon Brachytherapy in Glioblastoma”, Acta Neurochir (Wien) (1999) 141: 127-133. |
U.S. Appl. No. 11/981,182, filed Oct. 31, 2007, Jones et al. |
U.S. Appl. No. 11/980,976, filed Oct. 31, 2007, Jones et al. |
U.S. Appl. No. 12/321,244, filed Jan. 20, 2009, Acosta et al. |
International Search Report of PCT/US2009/000402 mailed Apr. 15, 2009. |
Paul V. Harper, “Some Therapeutic Applications of Radioisotopes”, Journal of the Mississippi State Medical Association, Oct. 1966, vol. VII, pp. 526-533. |
“Variable shield for radiation-therapy source wire and centering catheter”, Research disclosure, Mason Publications, Hampshire, GB, vol. 438, No. 48, Oct. 2000, XP007126916. |
Gregory K. Edmundson et al., “Dosimetric Charateristics of the Mammosite RTS, a New Breast Brachytherapy Applicator”, Int. J. Radiation Oncology Biol. Phys, vol. 52, No. 4, pp. 1132-1139, 2002. |
Melvin A. Astrahan, PhD et al., “Optimization of Mammosite therapy”, Int. J. Radiation Oncology Biol. Phys, vol. 58, No. 1, pp. 220-232, 2004. |
Philip H. Gutin, et al., “A coaxial catheter system for after loading radioactive sources for the interstitial irradiation of brain tumors”, J. Neurosur, vol. 56, pp. 734-735, 1982. |
R. D. Ashpole et al., “A New Technique of Brachytherapy for Malignant Gliomas with Caesium-137; A New Method Utilizinga Remote Afterloading system”, Clinical Oncology, (1990). |
Tanderup, et al, “Multi-Channel Intracavitary Vaginal Brachytherapy Using Three-Dimensional Optimization of Source Geometry”, Radiation & Oncology Journal of the European Society for Therapeutic Radiology and Oncology, 2004, pp. 81-85, Radiotherapy and Oncology 70 (2004), Elsevier Ireland Ltd. |
Devic, et al., “Advantages of Inflatable Multichannel Endorectal Applicator in The Neo-Adjuvant Treatment of Patients With Locally Advanced Rectal Cancer With HDR Brachytherapy”, Journal of Applied Clinical Medical Physics, Spring 2005, pp. 44-49, vol. 6, No. 2. |
Symon, et al. “Individual Fraction Optimization vs. First Fraction Optimization for Multichannel Applicator Vaginal Cuff High-Dose-Rate Brachytherapy”, pp. 211-215, Brachytherapy 5 (2006), Elsevier. |
Friedman, M, et al., “A New Technic for the Radium Treatment of Carcinoma of the Bladder”, Presented at the Thirty-fourth Annual Meeting of the Radiological Society of North America, Dec. 5-10, 1948, pp. 342-362. |
Walton, R. J., “Therapeutic Uses of Radioactive Isotopes in The Royal Cancer Hospital”, The British Journal of Radiology, 1950, pp. 559-599, William Heinemann, Publisher. |
Low-Beer, B. V. A., “Radioisotope Therapy”, “The Clinical Use of Radioactive Isotopes” 1950, pp. 284-349, Charles C. Thomas, Publisher, Springfield, Illinois, U.S.A., See pp. 343-349. |
Low-Beer, B. V. A., “The Therapeutic Use of Radioactive Isotopes”, “Practical Therapeutics”, Dec. 1954, pp. 69-87, vol. X, No. 6. |
Muller, J. H., “Radiotherapy of Bladder Cancer by Means of Rubber Balloons Filled in Situ With solutions of a Radioactive Isotope (Co60)”, Cancer, A Journal of the American Cancer Society, Jul.-Aug. 1955, pp. 1035-1043, vol. 8, No. 4, J. B. Lippincott Company, Philidelphia. |
Friedman, M, et al., “Irradiation of Carcinoma of The Bladder by a Central Intracavitary Radium or Cobalt 60 Source (The Walter Reed Technique)”, Presented at the Annual Meeting of the American Radium Society, 1955, pp. 6-31. |
Hewitt, C. B., et al., “Update on Intracavitary Radiation in the Treatment of Bladder Tumors”, The Journal of Urology; Official Journal of The American Urological Association, Inc., 1981, pp. 323-325, vol. 126 September, The Williams & Wilkins Co. |
Hieshima,G. B., et al. “A Detachable Balloon for Therapeutic Transcatheter Occlusions 1”, Technical Notes, Jan. 1981, pp. 227-228, vol. 138. |
Russel, A. H., et al, “Intracavitary Irradiation for Carcinoma of the Urinary Bladder: Rationale, Technique, and Preliminary Results”, Int. J. Radiation Oncology. Phys,. 1984, pp. 215-219, vol. 10, Pergamon Press Ltd. |
Yin, W., “Brachtherapy of Carcinoma of the Esophagus in China, 1970-1974 and 1982-1984”, Brachytherapy HDR and LDR, May 4-6, 1989, pp. 52-56. |
Kaufman, N., “Remote Afterloading Intraluminal Brachytherapy in The Treatment of Rectal, Rectosigmoid, and Anal Cancer: A Feasibility Study”, International Journal of Radiation Oncology, Biology, Physics, Sep. 1989, pp. 663-668, vol. 17, Issue 3, Pergamon Press plc. |
Wolf, C. D., et al., “A Unique Nasopharynx Brachytherapy Technique”, Official Journal of the American Association of Medical Dosimetrists, 1990, pp. 133-136, vol. 15, Issue No. 3., Pergamon Press. |
Fowler, J. F., “Brief Summary of Radiobiological Principles in Fractionated Radiotherapy”, Seminars in Radiation Oncology, Jan. 1992, pp. 16-21, vol. 2, No. 1, W. B. Saunders Company. |
Nag, S, “Modern Techniques of Radiation Therapy for Endometrial Cancer”, Clinical Obstetrics and Gynecology, Sep. 1996, pp. 728-744, vol. 39, No. 3, Lippincott-Raven Publishers. |
Pernot, M., “Combined Surgery and Brachytherapy in the Treatment of Some Cancers of the Bladder (Partial Cystectomy and Interstitial Iridium-192)”, Radiotherapy & Oncology, 1996, pp. 115-120, Elsevier Science Ireland Ltd. |
Micheletti, E., et al., “High-Dose-Rate Brachytherapy for Poor-Prognosis, High-Grade Glioma: (Phase II) Preliminary Results”, Tumori, 1996, pp. 339-344. |
Nag, S., et al., “Perineal Template Interstitial Barchytherapy Salvage for Recurrent Endometrial Adenocarcinoma Metastatic to the Vagina”, Necologic Oncology 66, 1997, pp. 16-19, Article No. GO974722, Academic Press. |
Nag, S., et al., “Remote Controlled High Dose Rate Brachytherapy”, Critical Reviews in Oncology/Hematology 22, 1996, pp. 127-150, Elsevier Science Ireland Ltd. |
Sylvester, J., et al., “Interstitial Implantation Techniques in Prostate Cancer” Journal of Surgical Oncology 1997; 66: 65-75, Wiley-Liss, Inc. |
Tan, L. T., et al., Radical Radiotherapy for Carcinoma of the Uterine Cervix Using External Beam Radiotherapy and A Single Line Source Brachytherapy Technique: The Clatterbridge Technique, The British Journal of Radiology, 70, date Dec. 1997, pp. 1252-1258. |
Kuettel, M. R., et al., “Treatment of Female Urethral Carcinoma in Medically Inoperable Patients Using External Beam Irradiation and High Dose Rate Intracavitary Brachytherapy” The Journal of Urology, May 1997, pp. 1669-1671, vol. 157, The American Urological Association, Inc. |
Slevin, N. J., et al., “Intracavitary Radiotherapy Boosting for Nasopharynx Cancer” The British Journal of Radiology, 70, Apr. 1997, pp. 412-414. |
Sneed, P, K., et al., Interstitial Brachytherapy Procedures for Brain Tumors, Seminars in Surgical Oncology 1997; 13: 157-166, Wiley-Liss, Inc. |
Dempsey, J. F., et al., “Dosimetric Properties of a Novel Brachytherapy Balloon Applicator for The Treatment of Malignant Brain-Tumor Resection-Cavity Margins” Int. J. Radiation Oncology Biol. Phys., May 1998, pp. 421-429, vol. 42, No. 2, Elsevier. |
Kolotas, C., et al., “CT Guided Interstitial High Dose Rate Brachytherapy for Recurrent Malignant Gliomas”, The British Journal of Radiology, 72, (1999), pp. 805-808. |
Demanes, D, J., et al., “The Use and Advantages of a Multichannel Vaginal Cylinder in High-Dose-Rate Brachytherapy”, Int. J. Radiation Oncology Biol. Phys., (1999), pp. 211-219, vol. 44, No. 1, Elsevier Science Inc. |
Debicki, M. P., et al., “Localized Current Field Hyperthermia in Carcinoma of The Cervix: 3-D Computer Simulation of SAR Distribution”, International Journal of Hyperthermia, 1999, pp. 427-440, vol. 15, No. 5. |
Garipagaoglu, M, et al., “Geometric and Dosimetric Variations of ICRU Bladder and Rectum Reference Points in Vaginal Cuff Brachytherapy Using Ovoids”, Int. J. Radiation Oncology Biol. Phys.. 2004, pp. 1607-1615, Elsevier Inc. |
Bowsher, W. G., et al., “Update on Urology-Prostate Cancer, 4-Treatment of Local Disease”, European Journal of Surgical Oncology, 1995 pp. 679-682, vol. 21, No. 6. |
Voung, T, et al., “High-Dose-Rate Endorectal Brachytherapy in the Treatment of Loacally Advanced Rectal Carcinoma: Technical Aspects”, Brachytherapy 4, 2005, pp. 230-235, Elsevier. |
Harada, T, et al., “Transcystoscopic Intracavitary irradiation for Carcinoma of The Bladder: Technique and Preliminary Clinical Results”, The Journal of Urology, Oct. 1987, pp. 771-774, vol. 138, No. 4, The Williams & Wilkins Co. |
Hall, J. W., et al., “Histologic Changes in Squamous-Cell Carcinoma of the Mouth and Oropharynx Produced by Fractionated External Roentgen Irradiation”, Radiological Society of North America, 1948, pp. 318-350, 50/3/MAR. |
Hine, G. J., et al., “Isodose Measurements of Linear Radium Sources in Air and Water by Means of an Automatic Isodose Recorder”,The American Journal of Roentgenology and Radium Therapy, 1950, pp. 989-998, vol. 64, No. 6, The Societies. |
Walton, R. J., et al., Radioactive Solution (24Na and 82 Br) in the Treatment of Carcinoma of The Bladder:, British Medical Bulletin, 1952, pp. 158-165, Medical Dept., The British Council. |
Marshall V. F., et al., “Current Clinical Problems Regarding Bladder Tumors”, Symposium on Bladder Tumors, 1956, pp. 543-550, 9/3/May-Jun., J. B. Lippincott Co, Etc. |
Hewitt, C. B., et al., “Intracavitary Radiation in the Treatment of Bladder Tumors”, The Journal of Urology, vol. 107, Apr. 1972, pp. 603-606, The Williams & Wilkins Co. |
Rotman, M., et al., “The Intracavitary Applicator in Relation to Complications of Pelvic Radiation—The Ernst System”, Int. J. Radiation Oncology Biol. Phys., 1978, pp. 951-956, vol. 4, Pergamon Press Inc. |
Nag, S., et al., “The Future of High Dose Rate Brachytherapy”, High Dose Rate Brachytherapy: A Textbook, 1994, pp. 447-453, Futura Publishing Company, Inc. , Armonk, New York 10504. |
Wang, C. C., “Carcinoma of the Nasopharynx”, Radiation Therapy of Head and Neck Neoplasms, 1997, pp. 257-280, Chapter 10, Wiley-Liss, Inc. |
Gaspar, L. E., et al., “Esophageal Brachytherapy”, Principles and Practice of Brachytherapy, 1997, pp. 305-321, Futrua Publishing Company, Inc., Armouk, New York. |
Vicini, F. A., et al, “Dose-Volume Analysis for Quality Assurance of Interstitial Brachytherapy for Breast Cancer”, Int. J. Radiation Oncology Biol. Phys., vol. 45, 1999, pp. 803-810, Elsevier Science Inc. |
Akagi, Y, et al., “Optimum Fractionation for High-Dose-Rate Endoesophageal Brachytherapy Following External Irradiation of Early State Esophageal Cancer”, Int. J. Radiation Oncology Biol. Phys., vol. 43, 1999, pp. 525-530, Elsevier Science, Inc. |
Xu, Z., et al., “Calculation of Dose Distribution Near an Innovative Concentric Balloon Catheter for Endovascular Brachytherapy”, Cardiovascular Radiation Medicine 2, 2000, pp. 26-31, Elsevier Science Inc. |
Stubbs, J. B., et al., “Preclinical Evaluation of a Novel Device for Delivering Brachytherapy to the Margins of Resected Brain Tumor Cavities”, J. Neurosurg 96, Feb. 2002, pp. 335-343, vol. 96. |
Das, R. K., et al., “3D-CT-Based High-Dose-Rate Breast Brachytherapy Implants: Treatment Planning and Quality Assurance”, Int. J. Radiation Oncology Biol. Phys. 2004, pp. 1224-1228, vol. 59, No. 4, Elsevier Inc. |
Cuttino, L. W., et al., “CT-Guided Multi-Catheter Insertion Technique for Partial Breast Brachytherapy: Reliable Target Coverage and Dose Homogeneity”, Brachytherapy 4, 2005, pp. 10-17, Elsevier. |
Glasgow, G. P., et al. “Remote Afterloading Technology”, AAPM Report No. 41, 1993, pp. i-vi and 1-107, American Institute of Physics, Inc. |
Hoshino, T., “Brain Tumor Research Center”, Abstracts of the 11th Conference on Brain Tumor Research and Therapy, Journal of Neuro-Oncology 28, 1996, pp. 31-113. |
Number | Date | Country | |
---|---|---|---|
20090198095 A1 | Aug 2009 | US |
Number | Date | Country | |
---|---|---|---|
61062179 | Jan 2008 | US |